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Abstract
The success of transplantation depends on multiple factors, but the establishment 
of immune tolerant milieu is of critical importance. Hepatic environment consists 
of different cellular populations with prominent capacity to tolerate a huge range of 
antigens. Among them, regulatory T cells (Tregs) play an important role. They control 
the strength of immune reactions against non-self antigens and were shown to have an 
impact on the establishment of immune tolerance in the post-transplantation period. 
Furthermore, they impact a particular state after transplantation – operational toler-
ance. The abundant data show that Tregs might be manipulated, which suggests their 
further implementation as a treatment strategy. Tregs are also a very attractive target 
as a biomarker in the monitoring of post-transplantation period. Here, we review the 
particular role of Tregs among the broad spectrum of immune tolerance mechanisms 
of the liver in the light of the current directions of medical research.
Keywords: liver transplantation, regulatory T cells, immune tolerance, biomarker, 
operational tolerance
1. Introduction
Transplantation is the most beneficial approach to treat diseases, manifested by 
irreversible changes of the liver parenchyma. The success of transplantation depends on 
both the surgical operation and the development of an immune tolerant milieu in the 
post-transplantation period. In solid organ transplantation, the immunological mecha-
nisms that are naturally dedicated to the defense from foreign antigens (microbial, viral 
etc.), are directed towards HLA (MHC) molecules and allo-antigens of the graft. This 
powerful immune reaction may destroy the graft and compromise the beneficial effect 
of the transplant. In the routine clinical practice, the control of effector immune func-
tion is achieved through immune suppressive therapy. However, in kidney and liver 
transplantation a spontaneous development of immune tolerance where a particular T 
cells subset – regulatory T cells (Tregs) is supposed to play important role [1].
Thus, recent achievements in transplantation research motivate the focus on the 
immunological mechanisms in two directions. From one side, this is the continuous 
investigation on new and more relevant biomarkers for the monitoring of the post-
transplantation period and prediction of graft rejection. From the other side, is the 
need of new therapeutic opportunities that might be influenced by the scientific 
research on the fine immune mechanisms [2].
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Studies on Tregs are particularly intense in the field of transplantology precisely 
in connection with their suppressive function. Lots of data in the literature on their 
behavior in transplantation of solid organs as well as stem cells is present. While in 
kidney, heart and other transplants already have outlined trends in the dynamics 
and even the therapeutic application of Tregs [3], the situation with liver trans-
plantation (LT) is more special.
Patients with life-limiting liver disease, which may present in the form of acute 
liver failure, end-stage chronic liver disease, hepatic malignancy, or inborn meta-
bolic disorders need LT - liver function is heavily impaired as a result of irreversible 
morphological changes (Figure 1).
Whatever the cause, the outcome of liver transplantation depends on three 
main factors: the clinical approach, the immune characteristics of the liver, and the 
therapeutic provision of immunological tolerance.
2. Clinical aspects of liver transplantation
From a clinical point of view, the outcome of transplantation depends on the 
general condition of the recipient (MELD score in adults and PELD score in children) 
before surgery and the quality of the graft, surgical technique, postoperative care, 
immunosuppressive therapy. The operation is one of the largest in volume and com-
plexity in surgery in general. Most often in Europe and the United States the so-called 
“standard” LT is performed, in which an entire organ is transplanted - whole liver 
graft. Deceased liver transplantation (DLT) is not common in Asia and part of a living 
donor organ is used [4, 5].
In deceased, an organ donation is possible when the graft is from a donor who 
has been registered as brain dead (brain dead donor) and donation after  
cardiac death.
Liver transplantation from a living donor (LDLT) offers some advantages over 
cadaveric donation: determining the time of the operation, the graft is from a 
healthy person and is in optimal condition, the cold ischemia time is shortened. 
It is suitable for children due to the possibility of precise selection of the graft in 
Figure 1. 
Principal medical conditions that require liver transplantation.
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accordance with the patient’s weight. Choosing a donor candidate is sometimes 
difficult due to the presence of arterial variations combined with additional 
abnormalities in other vessels and the biliary tract [6]. LDLT is suitable in cases of 
rare diseases in patients under 1 year of age. Of the pediatric liver transplantations 
performed at Lozenets University Hospital, about 65.5% of the patients are in this 
age group, and between 10 and 18 years of age they are significantly fewer [7].
Another type is domino transplantation, but it is rarely performed. Indication 
for it is Familial amyloid polyneuropathy (FAP). The disease affects extrahepatic 
organs and liver function is preserved. This allows the liver of the FAP patient to be 
given to another patient, from whom (in turn) receives the damaged organ (domino 
effect) [8]. The main requirement for the FAP recipient is to be over 55–60 years 
old, in order to minimize the risk of developing the disease.
Partial transplantation is performed as a matter of urgency in two specific 
situations. The first is in acute liver failure, in order to support the damaged organ 
until its recovery. The graft is then removed and the immunosuppressive therapy 
is stopped. The second case is in patients with congenital functional or metabolic 
disorders that affect the liver. Implantation of the partial graft preserves its own 
organ, corrects metabolic abnormalities and does not require whole liver trans-
plantation [9]. In both situations, the transplant can be orthotropic or heterotropic.
A variant of the partial transplantation is the split-transplant, in which the two 
lobes are distributed between two recipients. In recent years, due to the increased 
number of patients on the waiting list and the small number of potential donors, the 
technique of split-liver transplantation has been applied in which in vivo /in situ or 
ex-vivo/ex-situ the liver is divided into two parts - right for adult transplantation and 
left for pediatric transplantation. In some cases, it is possible to use the split-tech-
nique for transplantation of two adults. It is preferable to perform split-LT in-vivo, 
which reduces the risk of biliary complications, hemorrhage and significantly reduces 
the cold ischemia time of the graft [4, 5]. The main condition is the ratio between the 
weight of the graft and the patient, which must be at least 0.8% [4, 10]. The aim is to 
ensure the long-term vital functions of the recipient.
The complexity of the operation creates preconditions for the occurrence of 
complications during and after the operation. In the postoperative period, the 
leading are vascular and biliary complications, stenosis of the anastomosis, risk of 
infection and others.
In the long term, the outcome of transplantation depends largely on the estab-
lishment of optimal post-transplant immune tolerance. Here the immunological 
features of the liver, which distinguish it from other organs, play a significant role.
3. Tolerogenic milieu of the liver
The liver is a metabolic organ with a principal role of the detoxification and 
nutrient storage, but also protein synthesis and production of biochemicals 
required for the digestion and growth.
Without a doubt, the liver is also an important element of the immune system. 
A broad range of parts of innate and adaptive immunity is synthesized inside like 
acute-phase proteins, cytokines, complement components etc. Indeed, the cells 
that populate the liver encompass not only those with metabolic function. A great 
variety of immune cells are found in the parenchyma. Liver sinusoidal endothelial 
cells (LSECs), Kupffer cells, dendritic cells, hepatic stellate cells (HSCs), natural 
killer (NK) cells, NKT cells and T cells are present in the liver interstitium. In 
addition, hepatic cells express surface receptors immanent for the innate immunity 
[11]. Altogether, they participate in the establishment of a particular milieu that 
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from one hand tolerates a broad range of gut-derived antigens continuously pass-
ing across and on the other hand, retain the capacity to set up an immune response 
against pathogens like bacteria and viruses.
The questions of how this community maintains an immunotolerant environ-
ment to nutritional antigens, provide effector response to pathogens and guarantee 
liver transplantation are of particular interest. Moreover, the graft rejection is 
relatively rare in LT as compared to other SOT.
The combination of particular anatomy, variety of cells, specific expression of 
HLA molecules [12] and sustained antigenic stimulation makes the liver a unique 
immunologic structure. The blood delivered by vena portae is rich in alimentary 
and other antigens, which in fact are tolerated by the healthy liver. Indeed, the basal 
levels of pro- and anti-inflammatory cytokines are constant, but change under 
pathologic conditions in etiology-dependent manner [13–15].
The liver primarily is a metabolic organ and this function significantly impacts 
its immunologic reactivity. The metabolism of carbohydrates and lipids has a 
particular impact. Absorbed by hepatocytes, they are collected as glycogen and 
lipoproteins. Further on, cholesterol, triglycerides and other intermediate metabo-
lites can trigger TLR signalization and inflammasome activation. The final result 
is the increased pro-inflammatory cytokines secretion followed by the initiation of 
different pathologic phenomena, liver fibrosis for example [16]. Another example 
demonstrates that metabolic variations in hepatocytes during hepatitis B and C 
infection can raise viral replication [17, 18].
Together with hepatocytes, dendritic cells and macrophages also participate 
in the hepatic cytokine regulation. The oxidative phosphorylation may switch to 
anaerobic glycolysis (effect Warburg) leading to stimulation of pro-inflammatory 
mediators synthesis [19, 20]. Succinate dehydrogenase can additionally influence the 
cytokine balance. Its high levels may activate Hypoxia induced factor-1 (HIF-1) and 
production of IL-1β, thus providing evidence for the direct communication between 
the cellular metabolism and inflammatory response [21]. IL-1β per se is an important 
player in the control of homeostasis by regulating sleep, feeding, temperature in 
healthy conditions [22]. In pathologic situations, IL-1β is a critical mediator of the 
inflammatory response through processing of pro-IL-1β by Caspase-1 via inflamma-
some [23, 24]. Other mechanisms can be also involved in the cleavage of pro-IL-1β 
into biologically active IL-1b. Among them are serine proteases-neutrophil elastase, 
proteinase 3, cathepsin G in neutrophils [25–27] and the spontaneous release of 
IL-1β following pyroptosis and necroptosis [28]. Not surprisingly, IL-1β levels were 
found increased in other, relatively frequent medical conditions like NAFLD [29].
4. Tolerogenic properties of liver cells
Hepatic cells represent a heterogeneous population where different liver resi-
dents have their own tolerogenic approach (Figure 2).
4.1 Hepatocytes
Parenchymal hepatocytes are the major population in the liver. Although being 
involved in metabolism, toxin neutralization and glycogen synthesis, they  function 
also as immune cells by expressing immune-associated molecules like pattern rec-
ognition receptors (PRRs), adhesion and major histocompatibility complex (MHC) 
molecules [30, 31]. The latter permit hepatocytes to act as antigen-presenting cells 
for CD8+ T cells and to trigger their activation and proliferation [32]. However, 
the particular hepatic environment does not ensure the required survival factors  
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for CD8+ cells and they rapidly undergo activation-induced apoptosis [33]. 
Interestingly, the inflammatory response can be accompanied by the expression of 
MHC class II molecules followed by antigen presentation to CD4+ T cells [34, 35]. 
Depending on the differentiation status of helper cells, they may undergo Th2 
differentiation of uncommitted CD4 T cells, or abrogated ability of previously dif-
ferentiated Th1 to secrete interferon-γ, and finally - switch of CD4 + T effector cells 
towards induced regulatory T cells (FoxP3 + CD25+) [33, 36] . Ergo, liver parenchymal 
cells have substantial tolerogenic potential directed to both CD4+ and CD8+ T cells. 
Whether all would be launch together or not need to be elucidated.
4.2 Liver sinusoidal endothelial cells
Liver sinusoidal endothelial cells (LSECs) are an important part of the reticu-
loendothelial system. They are highly specialized and form the lining of the 
hepatic sinusoids. Their characteristic morphology (abundant fenestrae) and the 
permanent exposition to the blood flow permit them to filter out blood antigens. 
From an immunological viewpoint LSECs are liver-resident antigen-presenting 
cells that might be considered as bridge between the innate and adaptive immunity. 
It is evidenced by the expression of TLRs and RIGs, which under stimulation, turn 
on the production of proinflammatory cytokines, upregulation of costimulatory 
molecules and release of cytokines, that affect T cells [13, 37]. In parallel, LSECs 
may present antigens to T cells although not being professional APCs as shown by 
the expression of MHC class I on the LSECs surface [15]. The question about MHC 
Figure 2. 
The mosaic of tolerogenic cells in the liver. On the table below are shown main tolerogenic mechanisms, 
employed by every population.
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class II expression is still not well clarified, although under specific conditions, 
LSECs may present antigens to CD4+ T cells inducing immune tolerance [38] . 
LSEC actively participate in the induction of tolerance. For example, in naïve CD8+ 
T cells, the cognate interaction triggers the expression of co-inhibitory B7-H1 but 
not the co-stimulatory CD80/86 molecules exclusively on LSEC but not DC, which 
together with increased costimulation via CD28 is critical for the induction of CD8+ 
T cell tolerance by LSEC [39].
4.3 Kupffer cells
Kupffer cells (KCs) are particular subset of macrophages, settled in the liver. 
They represent appr. 35% of the non-parenchymal liver cells and 90% of all 
tissue macrophages [40]. They are located in the sinusoids, thus being systemati-
cally exposed to gut-derived antigens, circulating immune cells and pathogens. 
The principle function of KCs is pathogen killing. However, KCs are armed with 
scavenger receptors, TLRs, complement receptors and antibody receptors, secrete 
cytokines and chemokines and express broad range of receptor molecules [41]. 
Thus, KCs not only participate in antimicrobial killing, but also are an active player 
in the immune network. Their primary function is the antigen presentation. They 
express MHC class I and class II molecules which together with other costimulatory 
molecules activate T cells. In healthy conditions, KCs promote immune tolerance in 
several ways – lower expression of MHC class II, B7–1, B7–2, CD40, PD-1/PD-1 L 
and possible involvement of IL-10, nitric oxide, TGF-b [38, 42]. Other mecha-
nisms include the ability of KCs to absorb and clear alloreactive antibodies in liver 
transplantation [43]. Conversely, when stimulated (through TLRs for ex.), KCs 
become potent activators of T cells and NK cells [44]. In animal models, depletion 
of graft Kupffer cells was beneficial for the graft acceptance [45]. The double sword 
performance of KCs needs to be investigated in details, especially in humans. In any 
case, the current knowledge clearly indicates the KCs impact heavily on the reactiv-
ity of the liver immune system.
4.4 Stellate cells
Hepatic Stellate cells (HSCs) are another subset with immune function. This 
relatively small population (5–10% of liver parenchymal cells) resides in the space 
of Disse and is primarily involved in the storage of retinoid droplets and vitamin A 
and regulation of blood flow in the sinusoids [32, 46, 47]. In the intact liver, they 
are quiescent cells. Once activated, they differentiate to myofibroblast and partici-
pate in hepatic fibrosis pathogenesis [48]. The second direction of their function is 
the immunosuppression. Study in animals and humans show that they are effec-
tive antigen presenting cells with tolerogenic capacity because of the expression 
of PD-L1, B7-H7 and Fas/Fas-L pathways [49–51]. When activated, HSCs induce 
myeloid derived suppressor cells and Foxp3+ regulatory T cells by production of 
retinoic acid [52] In addition, they produce a broad range of cytokines, like TGF-b, 
IL-6 etc., and are able to respond to them, thus actively participate in the immune-
mediated network in the liver [48].
4.5 Liver dendritic cells
Dendritic cells (DCs) are professional antigen-presenting cells. Following the 
antigen processing, they activate T cells and unlock the adaptive immune reaction. 
The liver-resident DCs are distinct population as compared to blood DCs. While 
DCs expressing CD1c and CD14 represent 95% of blood DCs, in liver they are 70% 
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and those expressing CD141 increase up to 30% [53]. It is still unclear in details 
how these cells contribute to the development of immune tolerance. Although 
some evidences that DCs may enhance graft rejection by increase of CD80 and 
CD86 expression [54, 55], the depletion of donor DCs is followed by graft rejec-
tion [56]. The investigations of Bamboat et al. demonstrate that liver DCs gener-
ate more suppressive CD4+CD25+FoxP3+ T regulatory cells and IL-4-producing 
Th2 cells via an IL-10-dependent mechanism [57]. Another particular feature 
of LDCs is their low endocytosis capacity and weak capacity to stimulate T cells. 
Conversely, they produce high levels of the immunosuppressive IL-10 [58, 59]. The 
comparison with their splenic match reveal important differences: lower secretion 
of type I interferons, “lipid-based dichotomy” – lipid contents dependent antigen 
presentation, plasmacytoid DC (B220+) account for 19% of liver DC, but only 5% 
of spleen DC [60–62].
4.6 NK, ILC cells and NKT cells
Natural killer cells represent 30–50% of hepatic lymphocytes [63]. They 
differ from conventional NK cells and are closer to innate lymphoid cells (ILCs). 
In mouse they are closer to ILCs1, because of the expression of NK1.1 (CD161), 
CD69, CD49a NKp46, TRAIL. Both in mouse and human, these cells express 
CD49a and CD69 and secrete IFN-g and TNFa, but have weak suppressive capac-
ity [64]. The third subset NKT cells are well presented in the liver. Different 
subsets are differentially presented in mice and humans, but have similar func-
tion – support immune homeostasis, control autoimmune reactions and immune 
responses to microbial and viral infections and cancer [65]. Of particular interest 
are invariant NKT and mucosal-associated invariant T cells (MAIT). They are 
CD3+CD4−CD161+Vα7.2+ cells and have robust IFN-g and granzymes B response 
to inflammatory signal, but limited responsiveness when stimulated directly via 
TCR [66, 67].
Therefore, the proper hepatic cells have dual function. On one hand they are 
involved in metabolic processes in the liver and on the other – they participate in 
immune-mediated reactions per se and by carrying out the function of a bridge 
between biochemical reactions and immune pathways.
Hepatic cells interact with local immune cells and thus actively participate in 
the establishment of a sustained immune tolerant milieu. Zheng and Tian (2019) 
analyzing current data, highlight the death of effector cells and the “education” 
of regulatory cells as key processes leading to the development of liver tolerance. 
Additionally, they describe a broad spectrum of baseline immune mechanisms 
responsible for the state of hyporesponsiveness – clonal deletion, clonal anergy, 
clonal deviation, T cell dysfunction/exhaustion, education etc. [68].
5.  Regulatory T cells – conditio sine qua non for liver transplantation 
tolerance
5.1 General characteristics of regulatory T cells
Regulatory T cells are considered as the effector cellular arm of immune 
tolerance. Since the first publication of Kojima (1976), there is a constantly 
growing interest towards Tregs – cellular properties and medical applications 
[69]. Along with their unique suppressive phenotype (CD25 + FoxP3 + CD4+ T 
cells) [68, 69], Tregs express broad range of molecules that mirror their affilia-
tion to the population of T cells and are widely applied in research and medical 
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practice. Similarly to conventional T cells, they may be differentiated as naïve and 
memory, based on the expression of CD45RA, recent thymic emigrants (CD31), 
activated (HLA-DR) etc. [70, 71]. Their trafficking is ensured by the expression 
of chemokine receptors [72, 73].
The hallmark of Tregs is the expression of the transcription factor FoxP3 [68]. It 
controls the transcription program of Tregs by regulating several genes – increases 
expression of Il2ra (CD25), Ctla4 (CTLA-4), Tnfrsf18 (GITR), but inhibits those of 
Il2. At the same time Foxp3 is subject of a tight regulation, where STAT5 signaling 
pathway is probably of key importance [74–77]. One may say that this is as two 
step process, starting with the generation of CD25hi, but FoxP3− Tregs-precursors, 
followed by the induction of FoxP3 through cytokine/STAT5-dependant signals 
involving HDAC [74, 78, 79]. Blocking of JAK/STAT pathway downmodulates Foxp3 
expression [80]. In addition, a group of studies indicate that the maintenance of 
Tregs suppressive function is dependent on the epigenetic regulation of foxp3 locus 
by the Polycomb repressive complex 2 (PRC2). PRC2 consists of four subunits, pri-
marily of enhancer of zeste homolog 2 (EZH2), EED, SUZ12, and RbAp48, where 
EZH2 is of particular interest [81]. The function of EHZ2 differs among different 
T-cell populations, leading to variations in H3K27me3 levels and silenced genes. 
In FoxP3 negative cells, EZH2 deficiency is associated with autoimmune diseases, 
reduced number of Tregs and expansion of memory T cells [82, 83].
The origin of Tregs in periphery is still a hot topic. Clear evidences show that 
a subset of Tregs - thymic Tregs (tTregs), come directly from the thymus during 
the process of intrathymic maturation of T cells [84–86]. Their selection occurs 
predominantly in the medulla during the negative selection by the high-avidity 
interactions between mTECs and thymocytes [87, 88], although some studies 
indicate that the process starts earlier, in the cortex [89]. Under specific conditions, 
like increased concentration of TGF-β, hormonal changes or continuous antigenic 
stimulation, Tregs can arise from naïve CD4+ T cells in periphery – inducible Tregs 
(iTregs) [90–92].
5.2 Tregs are armed by different suppressive mechanisms
Independently of the origin, Tregs are powerful immune suppressors. Both 
subsets use several approaches to regulate the strength of the immune response. 
Roughly, they are based on the expression of particular molecules, secretion of 
cytokines and consumption of IL-2 and might be categorized as contact-dependent 
and contact-independent.
Early studies demonstrated that the contact-dependent way is effectuate by the 
constitutive expression of CD152 (CTLA-4) by Tregs [93, 94]. The engagement of 
CD80/CD86 pathway activates tryptophan catabolism and expression of indoleamin 
2,3 dioxygenase (IDO) [95]. Another mechanism involves PD-1/PD-L1 [95]. It is 
effective both against autoreactive B cells [96] and T lymphocytes [97]. Dilek et 
al. using alloreactive human T cells and blocking antibodies, evidenced by live cell 
dynamic microscopy that CD28, CTLA-4, and PD-L1 differentially control velocity, 
motility and immune synapse formation in activated Teff versus Tregs [94]. Although 
natural, their expression on the Tregs surface is inducibly increased and ensures the 
negative regulation of different receptors mediated signaling cascades in the target 
cells [98, 99]. Thus, Tregs directly attenuate cellular proliferation and activation.
The second line is facilitated by the production of different soluble factors 
upon activation. Among them are the immunosuppressive cytokines IL-10, TGF-b 
[100, 101], IL-34 [102] and IL-35 [103, 104]; perforins and granzymes [105]. It 
should be also considered that Tregs are target of cytokines like the proinflam-
matory TNF-α. The exact effect needs to be precised because current data are 
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controversial. The study of Valencia et al. evidenced that treatment with anti-
TNF antibody (infliximab) increases FOXP3 mRNA and protein expression by 
CD4+CD25hi Tregs and restored their suppressive function [106]. Later on, Chen et 
al. shows that upon in vitro activation with plate-bound anti-CD3 Ab and soluble 
anti-CD28 Ab, Foxp3 expression by highly purified mouse Tregs is markedly 
downregulated. TNF partially abrogates this effect and stabilizes Foxp3 expression 
as this effect of TNF can be blocked by anti-TNFR2 Ab, but not by anti-TNFR1 Ab 
[107, 108]. In any case, the role of TNF-a needs to be further investigated because 
TNF-a plays important role in the inflammatory reactions, where Tregs are 
expected to be also involved.
Upon activation, effector T cells produce IL-2, which stimulates T cells prolifera-
tion and the expansion of the immune response. At the same time, Tregs are distin-
guished by the their high expression of CD25 [109]. These facts suggest that Tregs 
need IL-2 to survive [110, 111]. Placed in an activated milieu, Tregs may compete with 
effector cells and as a result, decrease the levels of IL-2 in the environment. In fact, 
this is the third approach that Tregs apply to achieve a state of suppression [112, 113].
Regulatory T cells apply all of the above-mentioned approaches for the establish-
ment of immune-tolerant milieu. Still, there are no evidences about the mechanism 
preferred by nTregs or iTregs. Similarly, despite the abundance of data, no specific 
mechanisms can be attributed to a particular pathologic condition. Probably, the 
modus operandi of Tregs depends on the finetuning of T-cell receptor-antigen rec-
ognition and interaction, the target cell characteristics and the cytokine spectrum 
in the surrounding milieu.
5.3 The impact of regulatory T cells on the operational tolerance
The establishment of immune tolerance after solid organ transplantation (SOT) 
is the key therapeutic challenge in the post-operative period. In most cases, it is 
induced by the continuous application of immunosuppressive therapy. However, in 
some patients, a discontinuation of the regimen arrives, due to infections, cancer 
etc. Surprisingly, in some cases changes in immunological parameters, indicating 
the development of a state of immune tolerance were found despite the lack of 
immune suppression. This particular situation is defined as operational tolerance 
and is characterized by the absence of any clinical and histological signs of rejec-
tion in therapy free patients [114]. The operational tolerance (OT) is reported 
after transplantation of different solid organs, but is frequent in LT [115, 116]. It is 
supposed that tolerogenic properties of the liver and residential lymphocytes play a 
key role in this process [117]. The exact mechanisms are not fully clarified, but the 
intensive research highlights that it depends on multiple factors. Among them are 
regulatory T cells, particular gene expression profile and serum levels of HLA-G.
Regulatory T cells are the first parameter associated with OT. In patients 
with spontaneous tolerance they are increased independently of the age of 
recipient [118]. According to the study of Koshiba et al., not only the proportion 
CD4 + CD25high + T cells was increased in the tolerant patients’ peripheral lym-
phocytes and suppressed MLR specifically to the donor antigen, but also FOXP3 
expressing cells were present within the tolerant liver [119]. Pons and colleagues 
describe sustained increase in CD4 + CD25+ and CD4 + CD25hi cells in patients with 
operational tolerance in comparison with non-OT patients in a bimonthly evalua-
tion intervals until M16 [1].
Interestingly, in LT Tregs show a particular dynamic. In one of the earliest 
studies, pre-transplantation levels of Tregs were higher in patients than in controls. 
Lowest levels were observed at month 3 after Tx, followed by a relative increase at 
12 months and at later time points [120].
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The main question is why these cells are elevated in recipients? In fact, up to now 
reports discussing this topic in the literature are insufficient. The detailed study 
of Demirkiran and colleagues examined the presence and allosuppressive activity 
of CD4 + CD25 + Foxp3+ Tregs in perfusates of human liver grafts and monitored 
the cells presence in the circulation of recipients after liver Tx. The authors show 
an increased proportion of CD4 + CD25 + CTLA4+ T cells compared with healthy 
control blood. The increased percentages of Foxp3+ cells, which were negative for 
CD127, confirmed the enrichment of Tregs in perfusates. They suppressed prolifera-
tion and IFN-γ production of donor and recipient T cells. In vivo within the first 
weeks after Tx, up to 5% of CD4 + CD25 + CTLA4+ T cells in recipient blood were 
derived from the donor liver, indicating that a substantial number of donor Tregs 
detach from the liver graft during perfusion and continue to migrate into the recipi-
ent after Tx. These donor Tregs suppress the direct pathway alloresponses and may 
in vivo contribute to chimerism-associated tolerance early after liver Tx [121]. In a 
small number of patients, we found a pick in the percentage of Tregs at day 7 (D7) 
followed by a decrease until D30 being always around and above healthy controls 
values independently of the diagnosis or age. The simultaneous routine measure-
ment of liver function laboratory parameters revealed that the increase in Tregs pre-
cedes albumin synthesis restoration [122]. In another study Baumann et al. evidence 
that the benign clinical course of subclinical rejection (SCR) compared to acute 
clinical rejection (ACR) is associated with intrahepatic T cell infiltration patterns 
showing less cytotoxic T cells and more CD4 + FOXP3+ Tregs. They demonstrate that 
in patients with SCR the pattern of infiltrating T cells is characterized by a stronger 
accumulation of CD4+ cells, an increasing CD4+/CD8+ ratio, and an increasing 
CD4+ forkhead box P3 (FOXP3) + regulatory T cell (Treg)/CD8+ ratio, which 
was not seen in acute clinical rejection. These intrahepatic T cell patterns were not 
reflected in the peripheral blood [123]. Cumulatively, these data suggest the presence 
of particular sort of cellular chimerism, associated with liver transplantation.
The chimerism is a specific phenomenon characterized by the presence of cells 
from one individual in another. Microchimerism is reported in hematopoietic stem 
cells transplantation as a result of migration of passenger lymphocytes from the 
graft into recipient and in pregnancy (foetus). In SOT, microchimerism is described 
in mice first [124]. Among multiple reports showing than donor mononuclear cells 
migrate from the graft in the recipient, Jonsson et al. find that the peak levels of 
chimerism are within the first 48 hours after transplantation and the range reaches 
20% of total peripheral blood mononuclear cells [125, 126]. In a concise and very 
interesting review, Abrol and colleagues assume that increased expression of che-
mokines in the liver attracts alloreactive T cells that are subsequently destroyed by 
coming in contact with various liver cells inherently programmed towards tolerance 
induction [127]. Donor specific hypo-responsiveness, down regulation of T helper 
type I cytokine (IFN-γ) and no change in T helper type 2 cytokine (IL10) in the 
in vitro mixed lymphocyte reaction in recipients who achieved operational toler-
ance were also reported [128]. Indeed, this topic needs more studies directed to the 
detailed evaluation of different cellular subsets. Probably, Tregs might be part of 
passenger leucocytes or they might be secondary induced by the modified hepatic 
environment.
6. Other tolerogenic strategies
Tregs are not the only approach, involved in tolerance establishment in liver 
transplantation. Other cells also participate in by expressing particular molecules or 
changing their genetic pattern.
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In 16 operationally tolerant liver recipients, 16 recipients requiring on-going 
immunosuppressive therapy, and 10 healthy individuals by microarray profiling 
Martinez-Llordella et al. identified a gene expression signature that could discrimi-
nate tolerant recipients from immunosuppression-dependent patients with high 
accuracy. This signature included genes encoding for γδ T-cell and NK receptors, 
and for proteins involved in cell proliferation arrest. In addition, tolerant recipients 
exhibited significantly greater numbers of circulating potentially regulatory T-cell 
subsets (CD4 + CD25+ T-cells and Vδ1+ T cells) than either non-tolerant patients or 
healthy individuals [129].
The human leucocyte antigen-G (HLA-G) is a non-classical HLA class I mol-
ecule with prominent tolerogenic properties. It inhibits cytotoxicity and prolifera-
tion, but stimulates the development of regulatory T cells. HLA-G is present as a 
membrane-associated form and a soluble one. Interestingly, the uptake of HLA-G 
by some resting but mostly in activated CD4 and CD8 T cells leads to the instant 
generation of a new type of regulatory cells that initially act through cell-surface 
molecules that they temporarily display but do not express themselves [130–132]. 
This mechanisms is defined as trogocytosis and seems to play important role for 
the establishment of immune tolerance [133]. Several groups provides evidences 
about the role of HLA-G in kidney and heart transplantation [134–136]. In healthy 
conditions in adults, HLA-G is weakly expressed in liver, but it might be transmit-
ted through transendothelial migration and/or trogocytosis from circulating cells 
under particular circumstances like cytokines, hypoxia etc. [137–139]. In all cases, 
elevated levels of sHLA-G is associated with reduced risk of rejection and better 
survival [140, 141].
7. Clinical relevance of regulatory T cells for liver transplantation
Slowly, but without doubt, regulatory T cells are getting involved in the diag-
nostic process of many pathological conditions, expressed by deviations in immune 
tolerance – autoimmune [142, 143], tumors [144, 145], recurrent pregnancy loss 
[146, 147], primary immune deficiencies [110, 148] etc.
Current data indicate that Tregs have the potential to be a potential biomarker 
for the monitoring of the posttransplantation period [2]. Specifically, in liver 
transplanted patients Tregs are object of intensive research mostly because they 
are inherently involved in the operational tolerance and are part of natural liver 
toleragenic mechanisms. Despite the abundant data showing the benefit of Tregs 
determination during posttransplantation period, there are still many unresolved 
questions. Some of them are related to the definition of Tregs phenotype that 
should be used. Although identified as FoxP3 + CD4+ T cells, the expression of 
FoxP3 was demonstrated less informative than the promotore demethylation 
because it distinguishes true Tregs from transiently FOXP3+ activated T cells [149]. 
For diagnostic purposes, Tregs are often defined as CD127-CD25 + CD4+, but recent 
advances in the field showed a population CD25- [150], which is not fully character-
ized regarding CD127. Another direction that needs to be elucidated are Tregs in 
biopsies and peripheral blood. In Barcelona consensus (2016) several studies are 
shown with ambiguous results [151], that does not provide clear evidences for the 
relevance of Tregs measurement in posttransplantation period. The third direction 
is the significantly decreased expression of CD25 in relation to the immunosuppres-
sive therapy and the consecutive inability to find out CD25hiTreg cells in the periph-
ery. Although Tregs are highly informative regarding the operational tolerance 
[152], the question is still unresolved and more studies are required to determine the 
value of Tregs in the monitoring of post-transplantation period.
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It seems, that Tregs are more promising as a therapeutic approach for the control 
of immune activation and development of a state of immune tolerance. Early 
experimental studies demonstrated association between them and the delay in islet 
allograft rejection and long term survival [153, 154]. During last five years, together 
with other approaches [155], Tregs attract the medical interest in the field of GVHD 
and solid organ transplantation [156, 157]. Todo et al. in 2016 report phase I results 
clinical trial with ex vivo expanded recipient polyclonal Tregs in living kidney 
transplants. Despite variability in recipient’s renal disease, the expansion protocol 
produced Tregs which met all release criteria, expressing >98% CD4 + CD25+ 
with <1% CD8+ and CD19+ contamination and > 80% FOXP3 expression with 
stable demethylation in the FOXP3 promoter. Within recipients, expanded Tregs 
amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg 
therapy tested were safe with no adverse infusion related side effects, infections or 
rejection events up to two years post-transplant [158]. Another study undertook a 
direct comparison of the in vitro and in vivo functional activities of the different 
memory and naïve Treg subpopulations showing that the naive Treg is the Treg 
population that exhibits the ideal biological features of a Treg therapeutic while 
the highly suppressive memory Tregs should be purposefully excluded from a Treg 
therapeutic due to their low lineage delity, low proliferative capacity, and greater 
pro-inflammatory potential [159]. Recently published results from The ONE study 
demonstrates that regulatory cell therapy is achievable and safe in living-donor 
kidney transplant recipients, and is associated with fewer infectious complica-
tions, but similar rejection rates in the first year. Therefore, immune cell therapy 
is a potentially useful therapeutic approach in recipients of kidney transplant to 
minimize the burden of general immunosuppression [160].
Finally, the immune capacity of the liver depends on the local hepatic and 
immune cells that transitory populate it. The current research provides abundant 
data about the intercellular tolerogenic mechanisms. However, some points need 
to be better clarified from the scientific and medical point of view. Among them 
are the fine-tuning of common immunosuppressive therapeutics regarding 
regulatory T cells, biochemical mechanisms of interactions between hepato-
cytes and immune cells, whether immune parameters of activation/suppression 
might provide information in advance about the liver function, the impact of 
individual immunogenetic variations on the recovery and operational tolerance 
etc. We think that the immune system should be considered as important player 
in the liver tolerance network and involved in the post-transplantation period 
monitoring.
8. Conclusion
The liver is a unique structure, where immunological mechanisms meet meta-
bolic processes. The tightly regulated collaboration between them creates particular 
tolerogenic milieu that impacts the homeostatic state. Regulatory T cells are shown 
to play important role in these events. Their dynamic and function are promising 
for the further development of new biomarkers and treatment strategies in liver 
transplantation.
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